Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedAug 14, 2025
DataAggregated Company Financials
Companies553
  • 7D3.8%
  • 3M14.0%
  • 1Y-4.9%
  • YTD5.3%

The Biotech industry is up 3.8% in the last week, with Gilead Sciences up 8.9%. However, the industry is down 4.9% over the past year. Looking forward, earnings are forecast to grow by 25% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 14 Aug 2025US$1.0tUS$163.2b-US$14,658,010,083.9415.6x-70.7x6.4x
Sat, 12 Jul 2025US$985.4bUS$155.8b-US$23,408,172,286.8618.5x-42.1x6.3x
Mon, 09 Jun 2025US$951.3bUS$155.9b-US$23,930,730,032.6116.8x-39.8x6.1x
Wed, 07 May 2025US$949.3bUS$154.1b-US$25,408,936,426.3418.3x-37.4x6.2x
Fri, 04 Apr 2025US$791.2bUS$118.6b-US$37,117,653,368.2221.5x-21.3x6.7x
Sun, 02 Mar 2025US$850.7bUS$118.9b-US$37,265,127,499.9717x-22.8x7.2x
Tue, 28 Jan 2025US$983.3bUS$149.5b-US$26,320,225,889.8517.1x-37.4x6.6x
Thu, 26 Dec 2024US$990.4bUS$149.9b-US$26,369,148,329.0016x-37.6x6.6x
Sat, 23 Nov 2024US$1.0tUS$150.0b-US$26,559,949,256.4417x-37.7x6.7x
Mon, 21 Oct 2024US$908.0bUS$113.1b-US$35,950,283,773.0221.7x-25.3x8x
Wed, 18 Sep 2024US$929.9bUS$113.2b-US$35,966,527,614.9422.9x-25.9x8.2x
Fri, 16 Aug 2024US$870.9bUS$113.2b-US$36,254,285,538.6422.2x-24x7.7x
Sun, 14 Jul 2024US$1.2tUS$164.5b-US$28,119,714,352.8429.4x-42.5x7.3x
Tue, 11 Jun 2024US$1.2tUS$164.5b-US$26,797,092,425.0728.1x-43.3x7.1x
Thu, 09 May 2024US$1.1tUS$164.6b-US$26,520,766,232.3824.3x-42.5x6.8x
Sat, 06 Apr 2024US$1.1tUS$164.4b-US$23,433,178,577.0325x-47.8x6.8x
Mon, 04 Mar 2024US$1.2tUS$167.9b-US$21,330,880,627.7515.9x-56.4x7.2x
Wed, 31 Jan 2024US$1.4tUS$204.7b-US$22,654,596,727.0017.8x-63.8x7.1x
Fri, 29 Dec 2023US$1.4tUS$204.9b-US$22,192,805,164.0019.9x-62.8x6.8x
Sun, 26 Nov 2023US$1.2tUS$204.8b-US$22,013,452,568.0018.6x-55.7x6x
Tue, 24 Oct 2023US$1.2tUS$207.5b-US$13,040,981,709.0016.2x-93x5.8x
Thu, 21 Sep 2023US$1.3tUS$207.5b-US$12,879,934,249.0016.5x-99.1x6.1x
Sat, 19 Aug 2023US$1.3tUS$207.6b-US$12,299,327,844.0017.4x-102.8x6.1x
Mon, 17 Jul 2023US$1.1tUS$186.7b-US$15,968,283,125.0012.9x-71.1x6.1x
Wed, 14 Jun 2023US$1.2tUS$186.1b-US$15,943,311,093.0011.8x-73x6.3x
Fri, 12 May 2023US$1.2tUS$191.8b-US$11,762,653,395.0014.4x-98.3x6x
Sun, 09 Apr 2023US$1.2tUS$216.8b-US$5,729,497,835.0014x-203x5.4x
Tue, 07 Mar 2023US$1.1tUS$199.1b-US$4,903,297,889.0016x-233.9x5.8x
Thu, 02 Feb 2023US$1.2tUS$204.0bUS$1.9b15.1x622.3x5.7x
Sat, 31 Dec 2022US$1.1tUS$203.5bUS$1.7b14.3x663.2x5.6x
Mon, 28 Nov 2022US$1.1tUS$202.3bUS$1.3b14.6x845.5x5.6x
Wed, 26 Oct 2022US$1.1tUS$206.5bUS$5.5b16.4x198.7x5.3x
Fri, 23 Sep 2022US$1.0tUS$206.2bUS$5.7b14.1x180.9x5x
Sun, 21 Aug 2022US$1.1tUS$206.4bUS$7.3b16x147.7x5.2x
Price to Earnings Ratio

147.7x


Total Market Cap: US$1.1tTotal Earnings: US$7.3bTotal Revenue: US$206.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average 42.3x202320242025
Current Industry PE
  • Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 6.4x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
  • Revenues have also declined 7.5% per year, which is driving profits down.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.92%
Healthcare2.51%
Biotech3.85%
Biotech3.85%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GILD Gilead SciencesUS$120.148.9%
+US$11.9b		62.0%PE23.6x
ABBV AbbVieUS$201.472.6%
+US$9.1b		4.4%PE95.6x
INSM InsmedUS$122.8710.4%
+US$4.8b		64.1%PS65.2x
NTRA NateraUS$157.7014.2%
+US$2.8b		33.1%PS11x
VRTX Vertex PharmaceuticalsUS$395.922.7%
+US$2.6b		-16.0%PE27.9x

Latest News

ZLAB
US$35.63
Zai Lab
7D
-8.0%
1Y
119.3%
EXAS
US$44.91
Exact Sciences
7D
-4.3%
1Y
-20.3%
INSM
US$122.87
Insmed
7D
10.4%
1Y
64.1%
CAI
US$34.28
Caris Life Sciences
7D
18.4%
1Y
n/a
AMGN
US$289.33
Amgen
7D
1.6%
1Y
-10.3%

Statutory Profit Doesn't Reflect How Good Amgen's (NASDAQ:AMGN) Earnings Are

Aug 13
Statutory Profit Doesn't Reflect How Good Amgen's (NASDAQ:AMGN) Earnings Are
VRTX
US$395.92
Vertex Pharmaceuticals
7D
2.7%
1Y
-16.0%
AKRO
US$48.31
Akero Therapeutics
7D
-8.5%
1Y
103.3%
GILD
US$120.14
Gilead Sciences
7D
8.9%
1Y
62.0%
ABBV
US$201.47
AbbVie
7D
2.6%
1Y
4.4%
NTRA
US$157.70
Natera
7D
14.2%
1Y
33.1%
ADMA
US$17.20
ADMA Biologics
7D
-7.2%
1Y
-2.1%
INCY
US$85.85
Incyte
7D
9.8%
1Y
39.2%
BMRN
US$58.30
BioMarin Pharmaceutical
7D
-3.9%
1Y
-34.9%

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 06
Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
MTSR
US$30.87
Metsera
7D
-7.7%
1Y
n/a

Metsera (NASDAQ:MTSR) Is In A Good Position To Deliver On Growth Plans

Jul 31
Metsera (NASDAQ:MTSR) Is In A Good Position To Deliver On Growth Plans
SRRK
US$31.98
Scholar Rock Holding
7D
-7.6%
1Y
247.2%
SMMT
US$26.87
Summit Therapeutics
7D
-4.3%
1Y
126.4%